Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Incyte (INCY)

Incyte Q3 revenue rises 14% to $1.56 billion; $1.23 billion Vega charge drives loss

Mixed Impact 4 of 5 earnings

Incyte reported third-quarter 2026 total revenue of $1.56 billion, up 14% from a year earlier, and raised its full-year 2026 total net sales guidance to $5,210-$5,300 million. GAAP net loss was $784.8 million, or $3.86 per diluted share, compared with net income of $424.2 million ($2.11 per share) a year earlier, mainly because of a one-time $1.23 billion in-process R&D expense tied to the Vega Therapeutics acquisition.

Key points

  • Total revenue was $1.56 billion, up 14%; Opzelura net sales were $255 million, up 36%
  • GAAP net loss of $784.8 million ($3.86 per diluted share) vs. net income of $424.2 million ($2.11) in Q3 2025
  • One-time $1.23 billion IPR&D expense from the Vega Therapeutics acquisition; non-GAAP diluted loss was $3.60 per share
  • 2026 total net sales guidance raised to $5,210-$5,300 million from $5,130-$5,260 million; Opzelura guidance includes a one-time $246 million CMS-related benefit

The filing

CompanyIncyte (INCY)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:03 AM ET
Accession number0000879169-26-000063

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.